FILTER
FILTERED INTERVIEW RESULTS
Peter Soelkner
MANAGING DIRECTOR, VETTER PHARMA INTERNATIONAL
"Our mission will remain to provide reliable, efficient, and safe processes from development, aseptic filling, and visual inspection to parenteral packaging in an economically, ethically, and ecologically responsible manner."
Jeffrey Nau
PRESIDENT & CEO, OYSTER POINT PHARMA
"Our mission is to bring novel and transformative therapies to the anterior (front) chamber of the eye, particularly for the treatment of ocular surface disease."
Shuang Liu
CEO & FOUNDER, CONSYNANCE THERAPEUTICS
"Although each rare disease impacts a small population, the rare disease population is estimated to be 10% of the total population, meaning 25-30 million Americans have at least one rare condition."
Jay Roberts & Robert Fremeau
PRESIDENT AND CEO & CHIEF SCIENTIFIC OFFICER, VYANT BIO
"At Vyant Bio we are reinventing how drugs are discovered for complex neurological and neurodegenerative disorders by applying a human-first approach."
Andrea Pfeifer
CO-FOUNDER & CEO, AC IMMUNE
"AC Immune is combining diagnostics and therapeutics, and it has developed the tools to enable detection and clearance of specific pathological proteins underlying neurodegenerative diseases."
Trevor P. Castor
PRESIDENT & CEO, APHIOS CORPORATION
"In 2021, we focused on introducing our green pathogen reduction technology to biotechnology and pharmaceutical companies."
Jeff Butler
PRESIDENT, AMPAC FINE CHEMICALS, AN SK PHARMTECO COMPANY
"Outside of our manufacturing capabilities, AFC is investing and featuring AMPAC Analytical given the growing demand for pharmaceutical testing services."
Louis Kassa
PRESIDENT & CEO, PENNSYLVANIA BIOTECHNOLOGY CENTER (PABC)
"Our blueprint to success has manifested in six IPOs and over US$3 billion worth of company value created."
Jan Kengelbach
CEO, AENOVA GROUP
"While it's always easier to deny a certain service if you don't yet have the technical expertise in a particular area, in the long-term it is advantageous to explore the possibility of investing in that area with the customer."
Russell Trenary
PRESIDENT & CEO, OUTLOOK THERAPEUTICS
"If our ophthalmic bevacizumab is approved, we will potentially enhance the standard of care for patients with disorders like wet AMD, diabetic macular edema, and branch retinal vein occlusion by removing concerns related to off-label repackaged IV product."
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
Africa Energy 2024 - Pre-release
The pre-release edition of Africa Energy 2024 comprises analysis based on over 80 interviews with ministers and leading executives from IOCs, NOCs, independents, associations, investors and service providers, to provide an in-depth and holistic view of sub-Saharan Africa’s ever-evolving energy sector.
The pre-release edition of Africa Energy 2024 comprises analysis based on over 80 interviews with ministers and leading executives from IOCs, NOCs, independents, associations, investors and service providers, to provide an in-depth and holistic view of sub-Saharan Africa’s ever-evolving energy sector.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
